Novo Nordisk launched oral Wegovy in the U.S. while Medicare set co-pays for the bridge program, alongside soaring sales for Eli Lilly's drugs.

The entities involved

• Novo Nordisk →

  Danish pharmaceutical company

  • BridgeBio and Novo Nordisk have both made filings under the KXCO Ontology.Mon 10:09
  • CMS introduced the Medicare drug price negotiation program, and companies are facing challenges regarding pricing and market access.Mon 00:08
• Eli Lilly and Company →

  American pharmaceutical company

  • ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Mon 17:18
  • The FDA approved Olumiant for pediatric indications on September 1, 2026.Mon 05:59
• Medicare →

  US federal health insurance

  • Advocates are calling for guardrails on AI development following a recent hack of the Medicare system.Mon 15:20
  • Leaders call for slowing AI development pace, concurrent with an AI model built by OpenAI being hacked via the Medicare portal.Mon 15:20

Related events

• Novo Nordisk, Merck, and Eli Lilly are noted as large pharmaceutical rivals with recent drug approvals and market presence in the US.Jun 8
• Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.Aug 1
• Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.Sep 14
• Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.Jun 7
• Novo Nordisk launched its Wegovy pill in the German market.Sep 3